New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success

About this update from Sona Nanotech, Inc.

[{"type":"text","content":"New NCL Assessment of Sona's GNR Technology Highlights Process Improvement SuccessHalifax, Nova Scotia--(Newsfile Corp. - June 8, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the \"Company\" or \"Sona\") is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute's Nanotechnology Characterization Laboratory (\"NCL\"). In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant residue present following the chemical reaction necessary for the manufacture of Sona's proprietary gold nanorods. The assessment shows that the continued improvements in Sona's manufacturing process for gold nanorods have resulted in a significant reduction in free surfactant levels in nanorod dispersions, with the average dropping from 230.7 ug/mL in prior assessed batches to 34.6 ug/mL in the batches following the process changes. As with the NCL's prior assessments of earlier batches of Sona's gold nanorods, this new assessment did not detect any endotoxins or microbial contamination. \"Sona's laboratory has undertaken a manufacturing enhancement program in preparation for the production of the gold nanorods necessary for our anticipated pre-clinical trials and studies. This program has resulted in improved yields and reduced surfactant levels with no loss in stability or biocompatibility, as evidenced by these additional excellent NCL assessment results which we were very pleased to receive,\" Sona's CEO, David Regan, commented. Sona CSO, Len Pagliaro, PhD, commented, \"Sona's proprietary gold nanorod manufacturing process, which does not use the toxin cetyltrimethylammonium (\"CTAB\"), has now been improved on to further minimize the residual surfactant, yielding material better suited for use in vivo.\" The NCL has committed to continuing to work with Sona in its discussions with the US Food and Drug Administration (\"FDA\"), and it is anticipated that NCL assessments of Sona's proprietary gold nanorods could be used in a future potential FDA application for an investigational device exemption (\"IDE\") to support the biocompatibility of Sona's gold nanorods. The NCL was established by the Nationa...

More updates from Sona Nanotech, Inc.